<?xml version="1.0" encoding="UTF-8"?>
<p>The vascular endothelial growth factor (VEGF) isoforms were particularly attractive targets to inhibit angiogenesis
 <xref rid="CIT0009" ref-type="bibr">
  <sup>9</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0010" ref-type="bibr">
  <sup>10</sup>
 </xref>. The expression of VEGF during embryonic stages is high and is thought to play a crucial role in new (vasculogenesis) or pre-existing blood vessels (angiogenesis)
 <xref rid="CIT0011" ref-type="bibr">
  <sup>11</sup>
 </xref>. For certain solid tumours, overexpression of VEGF contributes to increased tumour growth and metastasis, which may be attributed to improved nutrient replenishment availability for the metabolising cell
 <xref rid="CIT0012" ref-type="bibr">
  <sup>12</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0013" ref-type="bibr">
  <sup>13</sup>
 </xref>. Vascular endothelial growth factor receptor-2 (VEGFR-2) is a subtype of tyrosine kinase receptor VEGF family (VEGFR-TK)
 <xref rid="CIT0014" ref-type="bibr">
  <sup>14</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0015" ref-type="bibr">
  <sup>15</sup>
 </xref>. It is responsible for normal and abnormal changes in vascular endothelial cells
 <xref rid="CIT0016" ref-type="bibr">
  <sup>16</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0017" ref-type="bibr">
  <sup>17</sup>
 </xref>. VEGFR-2 inhibition will affect tumour cell blood supply, inhibiting its development, proliferation, and metastasis. VEGFR signalling pathway inhibition is a key therapeutic target for tumour inhibition
 <xref rid="CIT0018" ref-type="bibr">
  <sup>18</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0019" ref-type="bibr">
  <sup>19</sup>
 </xref>.
</p>
